Biofunctionalized capillary platform with 3D matrix for efficient CTC capture. Manuscript 17 January 2017 Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. Circulating tumor cells (CTCs) in peripheral blood provide valuable genetic information for cancer diagnosis and overall disease monitoring. The analysis of “liquid biopsy” holds immense promise, as it may lead to new approaches for cancer treatment. This study reports an effective continuous-flow microchannel system for isolating CTCs using a transferrin-conjugated 3D matrix synthesized by crosslinking polyethylene glycol–Fe₃O₄ nanostructures. This design enables rapid and efficient capture of CTCs. The platform also allows the use of multiple microchannel units in series, which can enhance cell capture efficiency by increasing the frequency of cell–substrate contact. CTCs were captured with high efficiency even at low target cell concentrations, achieving approximately 90% capture efficiency at 25 cells per mL of blood. Furthermore, the study demonstrates that cell capture performance is influenced by topographic interactions between the nanostructure-based matrix and the cancer cells of interest. In addition, this work presents a proof of concept using a 3D microchannel system capable of simultaneously capturing and permanently eliminating CTCs from peripheral blood samples. The study also evaluates clinical samples from colon and breast cancer patients for the rapid isolation of CTCs. Conclusively, the platform demonstrates a strong capacity for cancer cell sorting, biological studies of CTCs, and investigation of cancer metastasis, potentially benefiting real-time liquid biopsy applications and early cancer prognosis. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTCs in recurrent and metastatic head & neck squamous cell carcinoma. Manuscript 20 July 2023 Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). Background: Liquid biopsy is emerging as a non-invasive tool that provides a personalized snapshot of primary and metastatic tumors. It aids in detecting early metastasis, recurrence, or resistance to the disease. We aimed to assess the role of circulating tumour cells (CTCs) as a predictive biomarker in recurrent or metastatic head and neck cancer, specifically head and neck squamous cell carcinoma (HNSCC). Methodology: Thirty-five patients receiving palliative chemotherapy underwent blood sampling (2 mL in an ethylenediaminetetraacetic acid (EDTA) vial) at baseline and at 3-month intervals. The CTCs were isolated and evaluated using anti-epithelial cell adhesion molecule antibody-based enrichment with the OncoDiscover platform. Results: CTCs were isolated from 80% of patients (n = 28), showing sensitivity of cell detection at baseline and at 3-month intervals. The median CTC count was 1 per 1.5 mL of blood, and the concordance with clinicoradiological outcomes was 51.4%. The median CTC count declined at 3 months in responders (1 (range: 0–4) to 0 (range: 0–1)), while non-responders showed an increase in levels (0 (range: 0–2) to 1 (range: 0–3)). Although CTCs positively correlated with progression-free survival (PFS) and overall survival (OS), the association did not show a significant difference between CTC-positive and CTC-negative patients at 3 months (PFS: 6 months versus 4 months; hazard ratio: 0.68; 95% confidence interval (CI): 0.29–1.58, p = 0.323; OS: 10 months versus 8 months; hazard ratio: 0.54; 95% CI: 0.18–1.57; p = 0.216). Conclusion: This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Explore scientific publications from Actorius covering circulating tumor cells, liquid biopsy technologies, and innovations in cancer diagnostics and monitoring. Publications Research That Shapes the Future of Oncology Access studies, scientific papers, and published findings advancing cancer diagnostics and care. 17 March 2026 Read More ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. 17 March 2026 Read More ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. 17 March 2026 Read More ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. 17 March 2026 Read More AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. 17 March 2026 Read More ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. 17 March 2026 Read More AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. 7 March 2026 Read More AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. 3 November 2025 Read More PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. 3 November 2025 Read More Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. 3 November 2025 Read More Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. 3 November 2025 Read More Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. 17 October 2025 Read More Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. 16 September 2025 Read More PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. 16 September 2025 Read More Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. 3 June 2025 Read More PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. 3 June 2025 Read More Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. 3 June 2025 Read More Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. 3 June 2025 Read More Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. 3 June 2025 Read More Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. 9 May 2025 Read More Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. First Prev 1 Page 1 Next Last Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Dual ctDNA and CTC biomarkers improve detection of cancer progression. Publications 3 June 2024 ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Background Genomic mutations identified from circulating tumor DNA (ctDNA) have been shown to correlate positively with clinical disease status. EGFR and intracellular cell progression and proliferation pathways involving BRCA1/2 and TP53 genes drive high ctDNA load in progressive cancer patients. Circulating tumor cells (CTCs) indicate cellular residual disease (CRD). Together, ctDNA and CTCs as dual biomarkers offer predictive insights into tumor progression and metastasis, which may be valuable for early detection and treatment modifications. Methods In a retrospective study, 96 cancer patients (including lung, colorectal, breast, stomach, and other cancers) who had recently undergone treatment were investigated for the presence of CTCs and genomic mutations from ctDNA using the OncoMonitor test. Libraries were prepared using a hybridization-capture method covering 1000 targets with a mean sequencing depth of 5000× on the Illumina NextSeq 2000 platform. The test detected genomic alterations including single nucleotide variations (SNVs), small insertions and deletions (INDELs), copy number variations (CNVs), and translocations (fusions) using a 96-gene panel. CTCs were isolated using the OncoDiscover platform and identified as CK18+, PD-L1+, CD45- cells in 1.5 ml of blood. Results Among the 96 pan-cancer patients, 15.6% (n = 15) were identified with localized progressive disease without metastasis based on radiological findings, of which 60% (n = 9) showed at least one genomic alteration detected from ctDNA. Additionally, 12.5% (n = 12) patients were identified with metastatic disease from radiological findings, of which 58.3% (n = 7) showed the presence of at least one CTC. Among these, 33.3% (n = 4) patients had two CTCs, while five patients had no detectable CTCs. Furthermore, metastatic patients showed ctDNA load in 66.6% (n = 8) of cases with at least one genomic finding. In the metastatic disease cohort, CTC enumeration showed a concordance of 58.3% (n = 7) with metastatic radiological findings, while genomic findings from ctDNA showed a concordance of 66.6% (n = 8) with metastatic radiological findings. Among 23.9% (n = 23) patients identified radiologically with stable or treatment-responsive disease, 73.9% (n = 17) had no detectable genomic mutations from ctDNA, and 26.0% (n = 6) were CTC-negative, consistent with radiological findings. However, 26.0% (n = 6) patients had at least one genomic finding, contributing to discordance with radiological findings. Overall, genomic findings from the dual biomarkers showed concordance with radiological findings in 26.6% (n = 4) patients with progressive disease, 41.6% (n = 5) patients with metastatic disease, and 17.3% (n = 4) patients with stable or treatment-responsive disease. Conclusions Patients with progressive and metastatic disease identified through radiological findings showed concordance with dual ctDNA and CTC biomarkers. The concordance of ctDNA in progressive disease and CTC detection in metastatic disease highlights the individual significance of these biomarkers and supports their combined use for monitoring disease status and guiding treatment decisions. Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Automated OncoMetastat device enables CTC removal to support cancer therapy outcomes. Publications 3 November 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Introduction Despite no radiological evidence of minimal residual disease, up to 25–50% of colorectal cancer (CRC) stage II–III and breast cancer cases experience relapse. Identifying patients at risk of recurrence remains challenging, as approximately 90% of cancer-related deaths are associated with metastasis. The role of circulating tumor cells (CTCs) in extravasation and seeding of distant organs is well established; however, their extracorporeal isolation has not been widely demonstrated in routine practice. Current ex vivo CTC isolation systems often require complex setups and extensive manual handling. In this study, we present an automated device designed to capture and remove CTCs from whole blood using biocompatible cartridges mediated by antibody- and transferrin-conjugated glass bead substrates. Methods We developed the OncoMetastat touchscreen-based operational control device, integrating six roller peristaltic pumps and a cartridge containing 680 targeting 2 mm glass beads functionalized with anti-epithelial cell adhesion molecule (EpCAM) antibodies and transferrin protein. The device housing (365 × 200 × 30 mm) contains a bi-spiral channel (95 × 95 × 10 mm) with 680 beads and eight cross-section channels (3.50 × 3.55 mm). A 3D-printed spring-loaded quick-release mechanism ensures secure tube attachment and rapid cartridge exchange. Flow performance, hemolysis, protein adsorption, and leukocyte interaction were evaluated using blood samples from healthy individuals and cancer patients across multiple cancer types, including breast, CRC, lung, and head and neck cancers. Pyrogenicity was assessed in rabbits according to ISO 10993-11 guidelines. Results The device maintained stable blood circulation at 0.5 mL/min for 5–10 mL whole blood samples using a dual snap-fit holder with a 2° angled offset. The peristaltic pump ensured consistent flow without compromising sample integrity. The bead-filled spiral channel effectively retained CTCs, while the integrated design reduced manual handling and improved reproducibility. Low hemolysis (1%), along with reduced serum protein and leukocyte interactions, was observed in both healthy and cancer patient samples. Selective CTC capture was demonstrated in 24 clinical samples across cancer types. All materials passed pyrogenicity testing, with no temperature elevation observed in accordance with guidelines. Conclusions The OncoMetastat device successfully depleted CTCs from cancer patient whole blood without adversely affecting blood components. The automated system provides stable blood flow and demonstrates proof of performance for extracorporeal CTC removal, with potential to enhance cancer therapy outcomes. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Cellulose-based transferrin nanocages for CTC enumeration in head & neck cancer. Manuscript 10 October 2020 Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Herein, we report a hierarchically organized, water-dispersible “nanocage” composed of cellulose nanocrystals (CNCs), magnetically powered by iron oxide (Fe₃O₄) nanoparticles to capture circulating tumor cells (CTCs) from the blood of head and neck cancer (HNC) patients. Capturing CTCs from peripheral blood is extremely challenging due to their low abundance, yet their enumeration is clinically validated in assessing progression-free survival in HNC patients. By engaging multiple hydroxyl groups along the molecular backbone of CNCs, Fe₃O₄ nanoparticles were coordinated onto the CNC scaffold. This structure was further modified through conjugation with the protein transferrin (Tf) to enable targeted capture of CTCs. Owing to the presence of Fe₃O₄ nanoparticles, the nanocages exhibited magnetic properties, allowing CTCs to be captured under the influence of a magnetic field. Tf–CNC-based nanocages were evaluated using blood samples from HNC patients and their CTC capturing efficiency was compared with the clinically relevant Oncoviu platform. The results demonstrated that CNC-derived nanocages efficiently isolated CTCs from patient blood, achieving approximately 85% capture efficiency relative to the standard platform. The capture efficiency was found to vary depending on the concentration of transferrin and Fe₃O₄ nanoparticles immobilized onto the CNC scaffold. We envision that the Tf–CNC platform holds significant potential in liquid biopsy applications for the isolation and enumeration of CTCs, enabling early detection of metastasis in cancer. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Magnetic nanocrystals capture tumour cells from blood samples Press Release 11 April 2024 Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Cellulose-based magnetic nanocrystals and nanofibres can capture circulating tumour cells (CTCs) from the blood samples of head and neck cancer patients. A magnet is used to separate the trapped tumour cells, which are then identified under a fluorescence microscope. This technique could potentially be used to monitor cancer progression in real time, says an international team, which included researchers at North Dakota State University, USA, the Tata Memorial Hospital in Mumbai, and Actorius Innovations and Research, and Dr. Vishwanath Karad MIT World Peace University, both in Pune. Click the below link to read the full article. Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

The POP device effectively removes CTCs from blood to reduce metastatic progression. Publications 15 July 2020 ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival. Background: The presence of circulating tumor cells (CTC) in the vascular system is a tell-tale signature of metastasis in epithelial origin cancers including lung, breast, colorectal and head and neck cancers. Noteworthy, about 90% of cancer deaths are due to the progression of metastasis. Yet, cancer therapy is focussed on inhibiting tumour growth and there is a paucity of options that target metastasis. We demonstrate the POP ‘device’ that removes circulating tumour cells (CTC) from a patient’s blood to reduce the metastatic progression and improve overall survival. Methods: We designed, multi-component glass beads enriched antibody EpCAM conjugate substrates as POP blood fluidic device. We characterized the substrate and accounted for the biocompatibility using whole blood of healthy volunteers. We evaluated, the acute toxicity of substrates using rat (Wistar Albino) whole blood (CPCSEA registration number: 941/PO/Re/S/06/CPCSEA; 31/07/2019) and further studied major histopathological tissues for any toxicity. Finally, we evaluated 06 cancer patients whole blood (1.5 mL) for capturing and for the elimination of CTCs. The captured cells were immuno-stained, and the optimal fluorescence acquisition intensity was critically quantified in accounting CK18 protein overexpression. Results: The multi-component antibody EpCAM based substrate exhibited efficient CTC capture ability with a mean capture efficiency ranging from 40% to 100 % when compared to the OncoDiscover CTC test approved by CDSCO/ drug controller general of India (DCGI). Furthermore, the substrate indicated high biocompatibility primarily exhibited by the absence of haemolysis on whole human blood. Additionally, the preliminary animal experiments in rats showed a 100% survival rate and negligible toxicity to major organs. Conclusions: Removal of circulating tumor cells as a therapeutics is highly implicated in improving the overall survival of epithelial cancer patients. Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Combined ctDNA and PD-L1 CTC testing improves lung cancer monitoring and response. Publications 3 June 2025 Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. Background Liquid biopsies analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) enable minimally invasive monitoring and testing of lung cancer across different stages. Approximately 90% of patients succumb due to metastasis. However, identifying patients with early metastatic signatures remains extremely challenging. In addition, monitoring minimal residual disease (MRD) and identifying patients at risk of recurrence is highly important. While the prognostic role of CTCs in predicting survival has been established in several cancers, the combined role of CTCs and ctDNA in monitoring disease aggressiveness, treatment response, and therapeutic decision-making has not been extensively explored. In this study, we investigated the combined roles of ctDNA and CTCs in monitoring disease aggressiveness and metastasis in lung cancer patients. Methods A cohort of 265 late-stage lung cancer patients was retrospectively analyzed for the co-occurrence of the dual biomarkers ctDNA and CTCs. The results were correlated in a quadrant-based model to assess clinical disease states derived from PET scans and histopathological examination (HPE) findings. Next-generation sequencing (NGS) was performed using the OncoMonitor dual biomarker assay, which includes CTC enumeration with PD-L1 expression analysis. CTC counts were determined using the OncoDiscover Liquid Biopsy Test, approved by CDSCO-India, from 1.5 mL of blood. Results CTC distribution ranged from 1 to 8 cells, with a mean value of 1.22. Among the patients, 75.47% (n = 200) were CTC-positive, and among these, 91.50% (n = 183) exhibited PD-L1 expression on their CTCs, with a mean PD-L1–positive CTC value of 0.99. Both biomarkers were positive (ctDNA⁺/CTC⁺) in 135 patients (50.94%). Only 19 patients (7.17%) were negative for both biomarkers (ctDNA⁻/CTC⁻). Additionally, 43 patients (16.23%) were ctDNA⁺/CTC⁻, while 68 patients (25.66%) were ctDNA⁻/CTC⁺. The ctDNA⁺/CTC⁻ cohort exhibited the highest metastatic rate at 62.8%, followed by the ctDNA⁺/CTC⁺ group at 57.0%. The ctDNA-positive cohort showed the highest proportion of progressive disease (20.2% and 18.6% in CTC⁺ and CTC⁻ subgroups, respectively). Mutations in EGFR, TP53, and KRAS were observed in 62.64% (166/265) of patients. Stable disease was observed in 29.4% of patients when both biomarkers were absent (ctDNA⁻/CTC⁻). Conclusions Overall, the ctDNA-positive cohort demonstrated higher rates of MRD, disease progression, and metastasis, with no cases of stable disease. The combined quadrant analysis of CTC-PD-L1 cells and ctDNA provides a non-invasive approach for monitoring disease progression, treatment response, complete remission, and early metastatic detection in lung cancer patients. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTCs, clusters, and PD-L1 expression indicate MRD and guide endometrial cancer care. Publications 3 November 2025 PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Introduction The risk of recurrence in non-metastatic endometrial cancer (EC) within 2–3 years is significant, ranging from 6% to 21%. Lymph node involvement is a key determinant of outcome prediction in patients with operable EC. To improve prognostic accuracy, particularly in the context of curative-intent surgery and adjunct therapy regimens, biomarkers such as circulating tumor cells (CTCs) have not been extensively evaluated in EC. The presence of CTCs as an occult disease component in EC may represent minimal cellular residual disease (MCRD) and could play a role in the metastatic cascade and invasion to distant organs. In this study, we evaluated the distribution of CTCs, their PD-L1 overexpression, and the occurrence of CTC clusters in EC patients. Methods A total of 154 blood samples were retrospectively analyzed, including 133 baseline and 21 follow-up samples (1.5 mL each). CTCs were isolated using the CDSCO India–approved OncoDiscover® CTC Test, which employs immunomagnetic enrichment targeting epithelial cell adhesion molecule (EpCAM). CTCs were identified based on immunocytochemical staining as CK18⁺, DAPI⁺, and CD45⁻ cells with distinct morphological features. Fluorescence imaging was performed using a Zeiss Axio Observer 7 microscope, and signal intensities were quantified to assess associations with clinicopathological parameters. PD-L1 expression on CTCs was evaluated through fluorescence-based immunostaining and quantified accordingly. Statistical analyses summarized total CTC counts, PD-L1–positive CTCs, and the presence of CTC clusters. Results A total of 336 CTCs were detected in 116 patients (75.3%). PD-L1 overexpression on CTCs was observed in 52.6% of samples (81 out of 154). Across all 154 patient samples analyzed, the mean values were 1.54 for total CTCs, 0.14 for CTC clusters, and 1.23 for PD-L1–positive CTCs. Notably, 21 patients (13.6%) demonstrated the presence of CTC clusters, accounting for 121 of the 336 total CTCs, suggesting more aggressive disease behavior. The highest proportion of patients belonged to the 61–70-year age group (41.55%). Conclusions This study demonstrates a high prevalence of CTCs in the endometrial cancer population. The presence of CTCs, CTC clusters, and PD-L1–overexpressing CTCs indicates occult minimal residual disease, disease aggressiveness, and potential progression toward metastasis. PD-L1 expression on CTCs may have implications for immunotherapy decision-making, particularly in situations where tissue biopsy is unavailable. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations | Lokmat Times Press Release 17 March 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Click the button below to read the full story Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Manuscript 27 April 2022 Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Wearable, point-of-care diagnostics, and biosensors are on the verge of bringing transformative changes in detection, management, and treatment of cancer. Bioinspired materials with new forms and functions have frequently been used, in both translational and commercial spaces, to fabricate such diagnostic platforms. Engineered from organic or inorganic molecules, bioinspired systems are naturally equipped with biorecognition and stimuli-sensitive properties. Mechanisms of action of bioinspired materials are deeply connected with thermodynamically or kinetically controlled self-assembly at the molecular and supramolecular levels. Thus, integration ofbioinspired materials into wearable devices, either as triggers or sensors, brings about unique device properties usable for detection, capture, or rapid readout for an analyte of interest. In this review, we present the basic principles and mechanisms of action of diagnostic devices engineered from bioinspired materials, describe current advances, and discuss future trends of the field, particularly in the context of cancer. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test